姓名： 赵迎超
专业技术职务：主任医师，副教授、硕士生导师
担任职务：协和医院肿瘤中心妇科肿瘤副主任，病区主任
研究方向：肿瘤放射生物学及放射增敏
E-mail：2006xh0836@hust.edu.cn
一、个人简介
华中科技大学附属协和医院妇科肿瘤内科副主任，肿瘤中心病区主任；
中国临床肿瘤学会（CSCO）妇瘤专委会委员、湖北省医师协会放射肿瘤治疗医师分会常委；中国临床肿瘤学会（CSCO）青年委员、中国抗癌协会（CACA）放疗专业委员会青年委员、中国医师协会放射治疗医师分会近距离治疗学组委员、中华放射肿瘤学会（CSTRO）泌尿肿瘤放射治疗学组委员、省妇幼保健协会宫颈疾病防治专业委员会副主委、市医学会放射肿瘤专业委员会常委等；主持国家自然科学基金多项，以第一或者通讯作者发表SCI论文30余篇，包括以第一作者在美国科学院院报（PNAS）上发表原创性论文两篇，以通讯作者在国际放射肿瘤学顶刊Radiotherapy and Oncology（俗称“绿皮”杂志）发表靶区勾画新建议等。
二、主持课题
①国家自然科学基金面上项目，SRT触发成纤维细胞通过CCL2调控巨噬细胞M2表型转化在NF2相关前庭神经鞘膜瘤放射抵抗中的作用，2020.01-2023.12，主持。
②国家自然科学基金青年项目，c-Met对NF2相关前庭神经鞘膜瘤放射敏感性的调节作用和机制研究，2016. -2018，主持。
三、发表论文
近5年第一或者通讯作者著述：
1.Zhao Yingchao#, Liu Pinan#，Zhang Na#，Chen Jie，Landegger Lukas D，Wu Limeng，Zhao Fu，Zhao Yanxia，Zhang Yanling，Zhang Jing，Fujita Takeshi，Stemmer-Rachamimov Anat ，Ferraro Gino B，Liu Hao，Muzikansky Alona，Plotkin Scott R，Stankovic Konstantina M，Jain Rakesh K*, Xu, Lei*.Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proceedings of the National Academy of Sciences of the United States of America,2018. 115（9）：E2077-E2084. (IF=13.450 JCR：Q1)
2.Zhang Jiaming#, Yin Minuo, Peng Gang*, Zhao Yingchao*. CRNDE: An important oncogenic long non-coding RNA in human cancers. Cell proliferation,2018. 51(3): e12440. (IF=8.755 JCR：Q1)
3.Liu Yan#, Zhao Rong, Chi Shuqi, Zhang Wei, Xiao Chengyu, Zhou Xing, Zhao Yingchao*, Wang Hongbo*. Is Upregulated by Estrogen and Promotes Epithelial-Mesenchymal Transition via p53 in Endometrial Cancer. Molecular cancer research: MCR,2020. 18(2):204-215. (IF=6.750)
4.Zhou Xing#, Xia Geqing#, Liu Yan, Xin Xiaoyan, Shi Rui, An Lanfen, Zhang Jun, Zhao Rong, Zhao Yingchao*, Wang Hongbo*. Analysis of carcinogenic signaling networks in endometrial cancer identifies RAB17 as a potential target. Journal of cellular physiology,2021. 236(1):328-339. (IF=6.398 JCR：Q1)
5.Xing Biyuan#, Guo Jianfeng#, Sheng Yuhan, Wu Gang*, Zhao Yingchao*. Human Papillomavirus-Negative Cervical Cancer: A Comprehensive Review. Frontiers in oncology,2020. 10:606335. (IF=6.122)
6.Zhang Jiaming#, Yin Minuo, Huang Junming, Lv Zhengtao, Liang Shuang, Miao Xiaoao, Huang Fang*, Zhao Yingchao*. Long noncoding RNA LINC00152 as a novel predictor of lymph node metastasis and survival in human cancer:a systematic review and meta ana-lysis.Clinica chimica acta; 2018.483:25-32. (IF=6.314 JCR：Q1)
7.Cheng Mingxia#, Wang Hongbo, Zhao Yingchao*, Li Gingling*. Efficacy and Prognostic Factors for Response to PD-1 Inhibitors in Advanced Cervical Carcinoma: A Retrospective Study. Drug Design, Development and Therapy,2022.16, 887–897. (IF=4.556)
8.Pu Congli #, Xing Biyuan #, Xu Kai*, Zhao Yingchao*. Glycosylation and its research progress in endometrial cancer. Clinical and Translational Oncology. 2022. 24(10):1865-1880 (IF=3.4)
9.Yu Chang#, Guilin Li#, Zhiyong Yang#, Guang Han, Xiangpan Li, Ye Zhao, Qin Yang, Gang Wu, Kunyu Yang*, Yingchao Zhao*, Inguinal nodal clinical target volume delineation based on ana-lysis of anatomical locations of normal and metastatic lymph nodes in pelvic malignant tumors. Radiotherapy and Oncology.2023.183:109634 (IF=6.9 JCR：Q1 )
10.Jiaming Zhang#, Baofang Zhang#, Congli Pu, Jiarui Cui, Kexin Huang, Hongbo Wang*, Yingchao Zhao*, Nanoliposomal Bcl‐xL proteolysis‐targeting chimera enhances anti‐cancer effects on cervical and breast cancer without on‐target toxicities. Advanced Composites and Hybrid Materials. 2023. 6:78 (IF=20.1 JCR：Q1)
11.Yuhan Sheng#, Baofang Zhang#, Biyuan Xing, Zhao Liu, Yu Chang, Gang Wu*, Yingchao Zhao*, Cancer-Associated Fibroblasts Exposed to High-Dose Ionizing Radiation Promote M2 Polarization of Macrophages, Which Induce Radiosensitivity in Cervical Cancer. Cancers (Basel). 2023;15(5):1620. (IF=6. 58 JCR：Q1)
12.Biyuan Xing#, Congli Pu #, Yunshang Chen #, Yuhan Sheng, Baofang Zhang, Jie Cui, Gang Wu*,Yingchao Zhao*, Insights into the characteristics of primary radioresistant cervical cancer using single-cell transcriptomics. Human cell.2023.10.1007 (IF=4.4)
13.Yao Jiang#, Kai Hong#, Yingchao Zhao*, Kai Xu*. Emerging role of deubiquitination modifications of programmed death-ligand 1 in cancer immunotherapy. Front Immunol. 2023.14:1228200 (IF=7.3)
